REPAIR-AMI: stem cells for acute myocardial infarction

Area of Science:

• Cardiology
• Regenerative Medicine
• Stem Cell Biology

Background:

• Acute myocardial infarction (AMI) remains a leading cause of mortality worldwide.
• Left ventricular ejection fraction (LVEF) is a key indicator of cardiac function post-MI.
• Stem cell therapy is being investigated as a potential treatment to improve outcomes after AMI.

Purpose of the Study:

• To evaluate the efficacy of intracoronary delivery of bone marrow mononuclear cells (BMCs) versus placebo in patients with ST-segment elevation myocardial infarction (STEMI).
• To assess the impact of BMCs on left ventricular function and adverse clinical events following percutaneous coronary intervention (PCI).

Main Methods:

• The Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial was a randomized, placebo-controlled study.
• Patients with STEMI undergoing successful PCI received either BMCs or placebo via intracoronary infusion.
• Left ventricular ejection fraction and clinical events were assessed at 4-month and 1-year follow-up, respectively.

Main Results:

• Patients treated with BMCs showed a significant improvement in LVEF at 4 months compared to placebo (+5.5% vs +3.0%).
• BMC treatment was associated with a statistically significant reduction in adverse clinical events at 1-year follow-up.
• The study demonstrated a potential benefit of stem cell therapy in improving cardiac function and clinical outcomes post-MI.

Conclusions:

• Intracoronary administration of BMCs shows promise in improving cardiac function and reducing adverse events in patients with AMI.
• Despite promising findings, further research is essential to address unresolved clinical and physiological questions.
• The future role of stem cell therapy for AMI will be defined by ongoing basic and clinical research.